TY - JOUR
T1 - Multigene testing in localized prostate cancer
AU - Ross, Ashley E.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.
AB - Currently, there are several commercially available multigene tests for risk stratification in prostate cancer. These tests have been validated retrospectively; however, prospective studies are needed to fully establish their clinical roles. In some cases, molecular studies may add value, and updated NCCN Guidelines recommend "consideration" of molecular tests under certain circumstances, such as to help ascertain the likelihood of death from conservative management, of biochemical progression after radical prostatectomy or external-beam therapy, and of developing metastasis after radical prostatectomy or salvage radiotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84995812448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995812448&partnerID=8YFLogxK
M3 - Article
C2 - 27226507
AN - SCOPUS:84995812448
SN - 1540-1405
VL - 14
SP - 659
EP - 662
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -